Latest News on Pfizer Inc. (PFE) Stock

  • What Investors Can Expect from Vanda Pharmaceuticals in 2018 [February 23 2018 03:17 PM]
  • What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Investors can expect a slew of critical developments from Vanda Pharmaceuticals (VNDA) in 2018. It expects to begin a tradipitant Phase 3 study in the first half of 2018 for atopic dermatitis and publish results from the tradipitant clinical study for the treatment of gastroparesis by the end of fiscal 2018. Read more about this Pfizer Inc. (PFE) news
  • Analyst Ratings for Vanda Pharmaceuticals and Peers in February [February 23 2018 03:17 PM]
  • What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Vanda Pharmaceuticals (VNDA) is a biopharmaceutical company with a focus on developing and commercializing innovative therapies. Vanda Pharmaceuticals has adopted a five-pronged business strategy with a goal of becoming a leading global biopharmaceutical company. Read more about this Pfizer Inc. (PFE) news




  • Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF® [February 23 2018 07:00 AM]
  • Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted positive opinions recommending that two Pfizer hematology medicines be granted marketing authorizations in the European Union . Read more about this Pfizer Inc. (PFE) news

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center